Vol 2, No 1 (2016) - Articles
Cost-effectiveness analysis of the health technologies for treatment of chronic lymphocytic leukemia AbstractPDF
Vol 8, No 1 (2022) - Original Article
Enfortumab vedotin for the treatment of patients with urothelial cancer after failure of the treatment with PD-1/PD-L1 inhibitor—cost-effectiveness analysis AbstractPDF (Bulgarian)
Vol 10, No 1 (2024) - Original Article
Reimbursement of biomarkers in oncology: advantages and economic analysis of their application for diagnostics as part of the personalized medicine аpproach AbstractPDF (Bulgarian)